MMIT Reality Check on IBS-C (Oct 2020)

According to our recent payer coverage analysis for the treatment of irritable bowel syndrome with constipation (IBS-C), combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for IBS-C treatments shows that under the pharmacy benefit, about 40% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In September 2020, the FDA authorized an investigational new drug (IND) application from Seed Health to evaluate the impact of its DS-01, a broad spectrum probiotic, on gut microbiota of patients with irritable bowel syndrome.

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

a-woman-feels-pain
December 15

MMIT Reality Check on Ovarian Cancer (4Q2023)

Read More
patient-in-hospital
December 8

MMIT Reality Check on Follicular Lymphoma (4Q2023)

Read More
woman-feels-pain-in-colon
December 1

MMIT Reality Check on Colorectal Cancer (4Q2023)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today